Device Trial Radar · NCT07830797
Absorbable Hemostatic Fluid Gelatin Trial
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
324
Planned (sponsor's estimate)
Start
Sep 8, 2026
Primary completion
Sep 8, 2026
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Medprin Regenerative Medical Technologies Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Southern Medical University, China; Xi'an Honghui Hospital; The Third Affiliated Hospital of Southern Medical University; Obstetrics & Gynecology Hospital of Fudan University; Zhejiang Provincial People's Hospital
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, single-blind, randomized controlled, non-inferiority trial evaluating the safety and efficacy of an absorbable hemostatic fluid gelatin for surgical hemostasis. Subjects are patients undergoing elective/semi-elective surgeries in General Surgery, Orthopedics, and Gynecology. The test group receives the investigational device, while the control group receives a marketed predicate device (SURGIFLO). The primary outcome is the 5-minute hemostasis success rate at the Target Bleeding Site (TBS).
Conditions
- Surgical Bleeding
Interventions
Absorbable Hemostatic Fluid GelatinDevice
Composed of fluid gelatin preloaded in a syringe with catheter components; gelatin derived from porcine skin. Applied to TBS and covered with moist gauze during surgery.
Absorbable Hemostatic Fluid Gelatin SURGIFLO Haemostatic MatrixDevice
This product is a flowable hemostatic material made from a porcine skin-derived gelatin matrix, intended to control bleeding from capillaries, veins, and small arteries during surgical procedures
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-Minute Hemostasis Success RateTime frame: Intraoperative (Day of surgery)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.